TUKYSA from Seagen won FDA approval for HER2-positive breast cancer in conjunction with chemotherapy (trastuzumab and capecitabine) to treat advanced unresectable or metastatic HER2-positive breast cancer.
The indication covers patients with brain metastases who previously received anti-HER2-based therapies for metastatic cancer.